Support great content
Help us bring you the AM insights that matter
AM in the time of COVID-19Bioprinting

Wistar Institute leveraging Allevi bioprinting for COVID-19 research

The Wistar Institute, a biomedical research center focused on studying cancer, immunology and infectious diseases, is collaborating with biofabrication company Allevi to explore the use of bioprinting technologies to fight COVID-19. Specifically, Allevi’s bioprinting platform will be used to 3D print lung models to study the effects of SARS-CoV-2.

The need for research and a deeper understanding of COVID-19 is still of critical importance. Today, over half a million people around the globe have died from the virus, and millions are suffering from it or at risk of contracting it. With this urgency driving them, Wistar and Allevi are hoping to study the mechanisms deployed by the virus to infect humans and figure out how they can be stopped. The combination of Allevi’s bioprinting platform and Wistar’s knowledge of immunology and virology – along with its biosafety level 3 capabilities – will hopefully enable the partners to achieve a breakthrough on this front.

WiStar Allevi

“We are accompanying the spectacular work from our peers in the scientific community and have identified tremendous potential for our platform to enable COVID-19 research in a much faster, yet physiologically relevant manner,” said Taciana Pereira, Allevi Vice President of Life Sciences and a co-principal investigator on the project. “We believe that scientists from all areas need to unite now to solve this crisis, so we are ecstatic to work with Wistar and Dr. David Weiner.”

The partnership will be spearheaded by Dr. David B. Weiner, PhD, the executive vice president and director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith Charitable Trust Professor in Cancer Research. He said: “We have been advancing scientific investigations aimed at the treatment and prevention of COVID-19, and we believe that Allevi’s innovative approach is an exciting modality to gain unique insights into the inner workings of the novel coronavirus.”

This is not the only bioprinting project that is being undertaken to fight COVID-19: San Francisco-based Prellis Biologics is exploring the potential of using 3D printed synthetic lymph nodes for the production of fully human COVID-19 antibodies.

Tags

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!